Metabolomics diagnosis of covid-19 from exhaled breath condensate

Elettra Barberis; Elia Amede; Shahzaib Khoso; Luigi Castello; Pier Paolo Sainaghi; Mattia Bellan; Piero Emilio Balbo; Giuseppe Patti; Diego Brustia; Mara Giordano; Roberta Rolla; Annalisa Chiocchetti; Giorgia Romani; Marcello Manfredi; Rosanna Vaschetto

doi:10.3390/metabo11120847

Metabolomics diagnosis of covid-19 from exhaled breath condensate

Elettra Barberis, Elia Amede, Shahzaib Khoso, Luigi Castello, Pier Paolo Sainaghi, Mattia Bellan, Piero Emilio Balbo, Giuseppe Patti, Diego Brustia, Mara Giordano, Roberta Rolla, Annalisa Chiocchetti, Giorgia Romani, Marcello Manfredi, Rosanna Vaschetto

Research output: Contribution to journal › Article › peer-review

Abstract

Infection from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) can lead to severe respiratory tract damage and acute lung injury. Therefore, it is crucial to study breath-associated biofluids not only to investigate the breath’s biochemical changes caused by SARS-CoV-2 infection, but also to discover potential biomarkers for the development of new diagnostic tools. In the present study, we performed an untargeted metabolomics approach using a bidimensional gas chromatography mass spectrometer (GCxGC-TOFMS) on exhaled breath condensate (EBC) from COVID-19 patients and negative healthy subjects to identify new potential biomarkers for the noninvasive diagnosis and monitoring of the COVID-19 disease. The EBC analysis was further performed in patients with acute or acute-on-chronic cardiopulmonary edema (CPE) to assess the reliability of the identified biomarkers. Our findings demonstrated that an abundance of EBC fatty acids can be used to discriminate COVID-19 patients and that they may have a protective effect, thus suggesting their potential use as a preventive strategy against the infection.

Original language	English
Article number	847
Journal	Metabolites
Volume	11
Issue number	12
DOIs	https://doi.org/10.3390/metabo11120847
Publication status	Published - Dec 2021

Keywords

Breath analysis
COVID-19
GCxGC-MS
Metabolomics
Noninvasive analysis

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.3390/metabo11120847

Cite this

@article{061c2dca297542b9b4dfc8125ac0e1d2,

title = "Metabolomics diagnosis of covid-19 from exhaled breath condensate",

abstract = "Infection from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) can lead to severe respiratory tract damage and acute lung injury. Therefore, it is crucial to study breath-associated biofluids not only to investigate the breath{\textquoteright}s biochemical changes caused by SARS-CoV-2 infection, but also to discover potential biomarkers for the development of new diagnostic tools. In the present study, we performed an untargeted metabolomics approach using a bidimensional gas chromatography mass spectrometer (GCxGC-TOFMS) on exhaled breath condensate (EBC) from COVID-19 patients and negative healthy subjects to identify new potential biomarkers for the noninvasive diagnosis and monitoring of the COVID-19 disease. The EBC analysis was further performed in patients with acute or acute-on-chronic cardiopulmonary edema (CPE) to assess the reliability of the identified biomarkers. Our findings demonstrated that an abundance of EBC fatty acids can be used to discriminate COVID-19 patients and that they may have a protective effect, thus suggesting their potential use as a preventive strategy against the infection.",

keywords = "Breath analysis, COVID-19, GCxGC-MS, Metabolomics, Noninvasive analysis",

author = "Elettra Barberis and Elia Amede and Shahzaib Khoso and Luigi Castello and Sainaghi, {Pier Paolo} and Mattia Bellan and Balbo, {Piero Emilio} and Giuseppe Patti and Diego Brustia and Mara Giordano and Roberta Rolla and Annalisa Chiocchetti and Giorgia Romani and Marcello Manfredi and Rosanna Vaschetto",

note = "Publisher Copyright: {\textcopyright} 2021 by the authors. Licensee MDPI, Basel, Switzerland.",

year = "2021",

month = dec,

doi = "10.3390/metabo11120847",

language = "English",

volume = "11",

journal = "Metabolites",

issn = "2218-1989",

publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",

number = "12",

}

TY - JOUR

T1 - Metabolomics diagnosis of covid-19 from exhaled breath condensate

AU - Barberis, Elettra

AU - Amede, Elia

AU - Khoso, Shahzaib

AU - Castello, Luigi

AU - Sainaghi, Pier Paolo

AU - Bellan, Mattia

AU - Balbo, Piero Emilio

AU - Patti, Giuseppe

AU - Brustia, Diego

AU - Giordano, Mara

AU - Rolla, Roberta

AU - Chiocchetti, Annalisa

AU - Romani, Giorgia

AU - Manfredi, Marcello

AU - Vaschetto, Rosanna

PY - 2021/12

Y1 - 2021/12

N2 - Infection from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) can lead to severe respiratory tract damage and acute lung injury. Therefore, it is crucial to study breath-associated biofluids not only to investigate the breath’s biochemical changes caused by SARS-CoV-2 infection, but also to discover potential biomarkers for the development of new diagnostic tools. In the present study, we performed an untargeted metabolomics approach using a bidimensional gas chromatography mass spectrometer (GCxGC-TOFMS) on exhaled breath condensate (EBC) from COVID-19 patients and negative healthy subjects to identify new potential biomarkers for the noninvasive diagnosis and monitoring of the COVID-19 disease. The EBC analysis was further performed in patients with acute or acute-on-chronic cardiopulmonary edema (CPE) to assess the reliability of the identified biomarkers. Our findings demonstrated that an abundance of EBC fatty acids can be used to discriminate COVID-19 patients and that they may have a protective effect, thus suggesting their potential use as a preventive strategy against the infection.

AB - Infection from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) can lead to severe respiratory tract damage and acute lung injury. Therefore, it is crucial to study breath-associated biofluids not only to investigate the breath’s biochemical changes caused by SARS-CoV-2 infection, but also to discover potential biomarkers for the development of new diagnostic tools. In the present study, we performed an untargeted metabolomics approach using a bidimensional gas chromatography mass spectrometer (GCxGC-TOFMS) on exhaled breath condensate (EBC) from COVID-19 patients and negative healthy subjects to identify new potential biomarkers for the noninvasive diagnosis and monitoring of the COVID-19 disease. The EBC analysis was further performed in patients with acute or acute-on-chronic cardiopulmonary edema (CPE) to assess the reliability of the identified biomarkers. Our findings demonstrated that an abundance of EBC fatty acids can be used to discriminate COVID-19 patients and that they may have a protective effect, thus suggesting their potential use as a preventive strategy against the infection.

KW - Breath analysis

KW - COVID-19

KW - GCxGC-MS

KW - Metabolomics

KW - Noninvasive analysis

UR - http://www.scopus.com/inward/record.url?scp=85121723763&partnerID=8YFLogxK

U2 - 10.3390/metabo11120847

DO - 10.3390/metabo11120847

M3 - Article

SN - 2218-1989

VL - 11

JO - Metabolites

JF - Metabolites

IS - 12

M1 - 847

ER -

Metabolomics diagnosis of covid-19 from exhaled breath condensate

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this